A randomized double - blind placebo - controlled cross - over trial of the impact on quality of life of continuing dexamethasone beyond 24   h following <font color="red">adjuvant_2</font> <font color="red">chemotherapy_2</font> <font color="red">for_2</font> <font color="red">breast_2</font> <font color="red">cancer_2</font> <font color="red">._2</font> 
<br>
<br> Uncertainty remains about the optimal anti - emetic regimen for control of delayed nausea and vomiting after adjuvant chemotherapy for breast cancer . <font color="red">Many_1</font> <font color="red">patients_1</font> <font color="red">receive_1</font> <font color="red">dexamethasone_1</font> <font color="red">but_1</font> <font color="red">complain_1</font> <font color="red">of_1</font> <font color="red">insomnia_1</font> <font color="red">,_1</font> <font color="red">anxiety_1</font> <font color="red">/_1</font> <font color="red">agitation_1</font> <font color="red">,_1</font> <font color="red">and_1</font> <font color="red">indigestion_1</font> <font color="red">._1</font> The aim was to determine if patients receiving chemotherapy for <font color="red">breast_1</font> <font color="red">cancer_1</font> prefer treatment with dexamethasone or placebo for prophylaxis against delayed nausea and vomiting , and to compare quality of life ( QOL ) between the two treatments . In this randomized , double - blind , cross - over trial , we compared oral dexamethasone ( 4   mg twice daily for 2   days ) versus placebo for <font color="red">chemotherapy_3</font> <font color="red">-_3</font> <font color="red">naïve_3</font> <font color="red">patients_3</font> <font color="red">with_3</font> <font color="red">breast_3</font> <font color="red">cancer_3</font> <font color="red">._3</font> All <font color="red">patients_1</font> received intravenous granisetron and dexamethasone pre - chemotherapy and oral granisetron on day 2 . Primary endpoints were : ( i ) patient preference ; ( ii ) difference between cycles in change of QOL from days 1 to 8 . <font color="red">Median_3</font> <font color="red">age_3</font> <font color="red">of_3</font> <font color="red">the_3</font> <font color="red">94_5</font> <font color="red">women_5</font> <font color="red">was_5</font> <font color="red">51_5</font> <font color="red"> _5</font> <font color="red">years_5</font> <font color="red">(_5</font> <font color="red">range_5</font> <font color="red">27_5</font> <font color="red">-_5</font> <font color="red">76_5</font> <font color="red">)_5</font> <font color="red">:_5</font> <font color="red">79_3</font> <font color="red">received_2</font> <font color="red">fluorouracil_2</font> <font color="red">/_2</font> <font color="red">epirubicin_2</font> <font color="red">/_2</font> <font color="red">cyclophosphamide_2</font> <font color="red">and_1</font> <font color="red">15_2</font> <font color="red">received_2</font> <font color="red">doxorubicin_2</font> <font color="red">/_2</font> <font color="red">cyclophosphamide_2</font> <font color="red">._2</font> Thirteen withdrew pre - cycle 2 with no differences between arms . Of <font color="red">80_1</font> <font color="red">patients_1</font> stating a preference , <font color="red">31_1</font> <font color="red">preferred_1</font> <font color="red">placebo_1</font> ( 39   % , 95   % CI : 28 - 50   % ) and <font color="red">37_1</font> <font color="red">(_1</font> <font color="red">46_1</font> <font color="red"> _1</font> <font color="red">%_1</font> <font color="red">,_1</font> <font color="red">95_1</font> <font color="red"> _1</font> <font color="red">%_1</font> <font color="red">CI_1</font> <font color="red">:_1</font> <font color="red">35_1</font> <font color="red">-_1</font> <font color="red">58_1</font> <font color="red"> _1</font> <font color="red">%_1</font> <font color="red">)_1</font> <font color="red">preferred_1</font> <font color="red">dexamethasone_1</font> <font color="red">;_1</font> <font color="red">12_1</font> <font color="red">had_1</font> <font color="red">no_1</font> <font color="red">preference_1</font> <font color="red">._1</font> There were no differences in intensity of vomiting , nausea , or time to onset of vomiting . There was greater decrease in global QOL ( p   =   0.06 ) when patients received dexamethasone . No other symptom / QOL domains differed significantly . In conclusion , no significant difference was found in patient preference , QOL , or symptoms regardless of whether dexamethasone or placebo was used after adjuvant chemotherapy .